Clinical trial
Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors
NCT00002587 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002587 |
|---|---|
| Title | Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors |
| Official title | A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH PACLITAXEL (TAXOL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | paclitaxel, topotecan hydrochloride |
| Enrollment | 20 |
| Start date | Sep 1, 1994 |
| Primary completion | Dec 1, 2000 |
| Completion | Dec 1, 2000 |
| First posted | May 11, 2004 |
| Last update posted | Jun 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: